The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
LYNX-3, the second pivotal Phase 3 trial in keratorefractive participants with visual disturbances under mesopic, low-contrast conditions, is ongoing with topline results expected in the first half of ...
SAN RAFAEL, CA, UNITED STATES, January 6, 2026 /EINPresswire.com/ — Rising Star Optometry is marking nearly two decades of continued service in the region, reflecting its long-term role in providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback